Search clinical trials for: Raltegravir (MK0518)

Total 315 results

Merck Sharp & Dohme LLC

Completed

Safety and Efficacy of an Investigational Drug in Human Immunodeficiency Virus (HIV)-Infected Patients Failing Current Antiretroviral Therapies (0518-005)(COMPLETED)

HIV Infections | Acquired Immunodeficiency Syndrome
Merck Sharp & Dohme LLC

Approved for marketing

Early Access of MK0518 in Combination With an Optimized Background Antiretroviral Therapy (0518-023)

HIV Infections
Merck Sharp & Dohme LLC

Terminated

MK0518 in the Treatment of HIV-Infected Patients Switched From a Protease Inhibitor Regimen (0518-032)(TERMINATED)

HIV Infection
Canadian Immunodeficiency Research Collaborative
National Institutes of Health (NIH)

Completed

Integrase Inhibitor (MK-0518) Viral Decay

HIV Infections

Canada
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Effect of Famotidine and Omeprazole on MK0518 (Raltegravir) Pharmacokinetics in Human Immunodeficiency Virus (HIV)-Infected Patients (0518-054)

HIV Infections | HIV-1 Infection
University of Pittsburgh
National Cancer Institute (NCI)

Completed

Pilot Study of Adding Raltegravir (MK-0518) to Antiretroviral Therapy in Patients With Low Level Viremia

HIV Infection

United States
National Institute of Allergy and Infectious Diseases...

Completed

Effect of Addition of Raltegravir (MK-0518) to PI- or NNRTI-Based ART Regimens in HIV Infected Subjects With Undetectable Viral Load

HIV Infections

United States
Kaiser Permanente
Merck Sharp & Dohme LLC

Completed

Evaluating the Effect of CHanging EnfuvirtidE to Raltegravir in HIV Infected Subjects (CHEER)

HIV Infections

United States
Angela Kashuba, PharmD
Merck Sharp & Dohme LLC

Completed

Study to Characterize the Pharmacokinetics of Raltegravir in the Gastrointestinal (GI) Tract of Healthy Male Volunteers

Healthy Volunteer

United States
Vanderbilt University

Completed

Genetic Predictors of Raltegravir Penetration Into Cerebrospinal Fluid

HIV Infections

United States
Merck Sharp & Dohme LLC
Covance

Completed

A Study of the Safety, Tolerability, and Antiretroviral Activity of Raltegravir (MK-0518) in Combination With Other Antiretroviral Therapies in Russian Children and Adolescents Infected With Human Immunodeficiency Virus (HIV-1) (MK-0518-248)

HIV Infection
St Vincent's Hospital, Sydney
Merck Sharp & Dohme LLC; The Alfred; Holdsworth House Medical Practice

Completed

Switch From Tenofovir to Raltegravir for Low Bone Mineral Density (TROP)

HIV Infections | HIV | Osteoporosis | Osteopenia

Australia
Merck Sharp & Dohme LLC

Completed

Safety, Tolerability, and Pharmacokinetics of Raltegravir (MK-0518) in Healthy Japanese Male Participants (MK-0518-851)

Human Immunodeficiency Virus (HIV) Infection

Japan
Kristine Patterson, MD
Merck Sharp & Dohme LLC

Completed

A Pilot Study to Characterize the Pharmacokinetics of Raltegravir in the Cervicovaginal Fluids of HIV-infected Women

HIV | AIDS

United States
New Mexico Cancer Care Alliance
American Cancer Society, Inc.

Completed

Pilot Study of Raltegravir and Cisplatin in Squamous Cell Carcinoma of Head and Neck

Head and Neck Cancer

United States
Germans Trias i Pujol Hospital
Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la...

Completed

Impact of MK-0518 (Raltegravir) Intensification on HIV-1 Viral Latency in Patients With Previous Complete Viral Suppression

HIV Infections

Spain
Sichuan Kelun Pharmaceutical Research Institute...

Not yet recruiting

A Study of SKB518 in Patients With Advanced Solid Tumors

Advanced Solid Tumors
Merck Sharp & Dohme LLC

Completed

A 2-Year Study of an Investigational Drug in Obese Patients (0557-011)

Obesity
Merck Sharp & Dohme LLC

Completed

A Study to Determine the Effects of MK0557 in Obese Subjects (0557-006)(COMPLETED)

Obesity
Merck Sharp & Dohme LLC

Completed

A 1-Year Study of an Investigational Drug in Obese Patients (0557-012)(COMPLETED)

Obesity
Millennium Pharmaceuticals, Inc.

Completed

MLN518 in Combination With Standard Induction Chemo. for Treatment of Patients With Newly Diagnosed Acute Myelogenous Leukemia

Acute Myelogenous Leukemia

United States
Imperial College London
4D pharma plc

Active, not recruiting

MRx0518 in Patients With Solid Tumours Waiting Surgical Removal of the Tumour (MICROBIOME)

Melanoma | Breast Cancer | Head and Neck Cancer | Ovarian Cancer | Lung Cancer | Prostate Cancer | Bladder Cancer | Renal Cancer | Urethral Cancer | Uterine Cancer

United Kingdom
Kirby Institute

Completed

Antiretroviral Therapy Intensification With Raltegravir or Addition of Hyper-immune Bovine Colostrum in HIV-1 Infected Patients With Suboptimal CD4+ T Cell Response (CORAL)

HIV Infections
University of North Carolina, Chapel Hill
National Institute of Allergy and Infectious Diseases (NIAID); Merck Sharp... and other collaborators

Terminated

MK-0518 Intensification And HDAC Inhibition In Depletion Of Resting CD4+ T Cell HIV Infection

HIV Infections

United States
Vyne Therapeutics Inc.

Terminated

A Study of MK0594 in Patients With Alcohol Dependence (0594-020)

Alcohol Dependence
Merck Sharp & Dohme LLC

Terminated

A Study to Assess the Effects of MK0812 on Disease Activity in Patients With Relapsing-Remitting Multiple Sclerosis as Measured by Magnetic Resonance Imaging (MRI)(0812-003)(COMPLETED)

Relapsing-Remitting Multiple Sclerosis
Merck Sharp & Dohme LLC

Completed

MK0916 in Patients With Type 2 Diabetes and Metabolic Syndrome (0916-005)

Diabetes Mellitus, Type 2 | Metabolic Syndrome
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety and Efficacy of an Investigational Drug in HIV Infected Patients (0518-004)(COMPLETED)

HIV Infections | Acquired Immunodeficiency Syndrome
medac GmbH

Recruiting

Treatment Of Steroid-Refractory Acute Graft-versus-host Disease With Mesenchymal Stromal Cells Versus Best Available Therapy (IDUNN)

Steroid-refractory Acute Graft-versus-host Disease

Spain, Germany, France, Poland, Sweden
Merck Sharp & Dohme LLC

Completed

Safety and Efficacy of MK0736 & MK0916 in Patients With Hypertension (High Blood Pressure)(0736-003)(COMPLETED)

Hypertension
Merck Sharp & Dohme LLC

Completed

Evaluation of the Safety and Efficacy of Reformulated Raltegravir (MK-0518) 1200 mg Once Daily in Combination With TRUVADA™ in Human Immunodeficiency Virus (HIV)-1 Infected, Treatment-Naive Participants (MK-0518-292) (onceMRK)

HIV Infection
Vyne Therapeutics Inc.

Completed

Safety and Efficacy of MK0594 to Treat Overactive Bladder (0594-003)

Overactive Bladder | Urinary Incontinence
Merck Sharp & Dohme LLC

Completed

MK0524 Seasonal Allergic Rhinitis Study (0524-005)(COMPLETED)

Seasonal Allergies
Merck Sharp & Dohme LLC

Terminated

A Study to Evaluate the Efficacy of MK0719 in the Prevention of Postoperative Dental Pain (0719-002)

Pain, Postoperative
Massachusetts General Hospital
Merck Sharp & Dohme LLC

Completed

Advanced Neuroimaging Evaluation of CNS Changes Associated With Efavirenz Therapy Switch to an Raltegravir-based Regimen

HIV | Neurotoxicity | HIV-associated Neurocognitive Disorder

United States
National Institute of Allergy and Infectious Diseases...
Eunice Kennedy Shriver National Institute of Child Health and Human Development...

Completed

Safety and Pharmacokinetics (PK) of Raltegravir in HIV (Human Immunodeficiency Virus)-Infected Children and Adolescents

HIV Infections

United States, Puerto Rico, South Africa, Argentina, Brazil, Botswana
ViiV Healthcare

Completed

A Drug Interaction Study Evaluating GSK2248761 and Raltegravir Pharmacokinetics in Healthy Adult Subjects

Infection, Human Immunodeficiency Virus

United States
4D pharma plc

Terminated

A Study of Live Biotherapeutic Product MRx0518 With Hypofractionated Radiation Therapy in Resectable Pancreatic Cancer

Pancreatic Cancer

United States
St Stephens Aids Trust

Completed

Pharmacokinetics (PK) Study of Once Daily Darunavir/Ritonavir and Twice and Once Daily Raltegravir in HIV-infected Subjects

HIV Infections

United Kingdom
Merck Sharp & Dohme LLC

Completed

Management of Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Antiretroviral (ARV) Combination Therapy Including Raltegravir (MK-0518-138) (RACING)

HIV Infections
Garden State Infectious Disease Associates, PA
GlaxoSmithKline

Completed

An Interaction Study to Assess Drug Levels in Fasting Healthy Adult Subjects

Healthy

United States
ViiV Healthcare
GlaxoSmithKline; Shionogi

Completed

A Study of GSK1349572 Versus Raltegravir (RAL) With Investigator Selected Background Regimen in Antiretroviral-Experienced, Integrase Inhibitor-Naive Adults (SAILING)

HIV Infections | Infection, Human Immunodeficiency Virus

United States, France, Netherlands, Spain, Taiwan, Australia, Belgium, Russian Federation, Canada, United Kingdom, Mexico, Italy, South Africa, Romania, Argentina, Hungary, Poland, Chile, Greece, Brazil
ViiV Healthcare
GlaxoSmithKline; Shionogi

Completed

A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily (SPRING-2)

Infection, Human Immunodeficiency Virus I

Germany, Spain, France, Australia, United States, Canada, United Kingdom, Italy, Russian Federation
ANRS, Emerging Infectious Diseases

Completed

Evaluation of Raltegravir During the Third Trimester of Pregnancy (ANRS 160 RalFE)

HIV-1 Infection | PREGNANCY

France
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Not yet recruiting

A Study of HS-10518 in Healthy Female Participants

Endometriosis
Bristol-Myers Squibb
Merck Sharp & Dohme LLC

Completed

DDI HV (ATV - Merck)

HIV Infections

United States
David A Wohl, MD
Merck Sharp & Dohme LLC

Completed

Raltegravir as Early Therapy in African-Americans Living With HIV Study (REAL)

HIV Infections

United States
Merck Sharp & Dohme LLC

Completed

MK0557 for the Treatment of Cognitive Impairment in Patients With Schizophrenia (0557-027)

Schizophrenia | Paranoid Schizophrenia
St Stephens Aids Trust

Completed

Raltegravir and Ezetimibe PK Study

HIV

United Kingdom
IrsiCaixa

Completed

Impact of Raltegravir Intensification on HIV-1-infected Subjects With Complete Viral Suppression Under Monotherapy With Protease Inhibitors

HIV-1 Infection

Spain

3

Subscribe